An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

NCT05543252 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
428
Enrollment
INDUSTRY
Sponsor class

Stopped Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.

Conditions

Interventions

Sponsor

UCB Biopharma SRL